Concepedia

Estelle Marrer‐Berger

EM

Statistics

Publications

6

Citations

606

H-Index

6

Active since

2020

Affiliations

Roche (Switzerland)(Current)

Roche Pharma AG (Germany)

Heidelberg University

Estelle Marrer‐Berger is an author at Roche (Switzerland) specializing in oncology, cancer immunology, and immunology.

ORCID

Publications per year

2020–2024

6

Publications

6

Patient-derived micro-organospheres enable clinical precision oncology

Shengli Ding, Carolyn Hsu, Zhaohui Wang et al. · Cell stem cell · 2022 · 209 citations · Full text

, , +10

CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity

Isabelle Solomon, Maria Amann, Anne Goubier et al. · Nature Cancer · 2020 · 195 citations · Full text

, , +14

Immune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies

Katharina T. Kroll, Mariana M. Mata, Kimberly A. Homan et al. · Proceedings of the National Academy of Sciences · 2023 · 74 citations · Full text

, , +17

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody

Christian Augsberger, Gerulf Hänel, Wei Xu et al. · Blood · 2021 · 68 citations · Full text

, , +14

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies

Gabrielle Leclercq-Cohen, Hélène Haegel, Anneliese Schneider et al. · Journal for ImmunoTherapy of Cancer · 2021 · 43 citations · Full text

, , +17

1–5 of 6